Christopher Bowden is Chief Medical Officer of AGIOS PHARMACEUTICALS, INC.. Currently has a direct ownership of 15,487 shares of AGIO, which is worth approximately $890,657. The most recent transaction as insider was on Jun 18, 2021, when has been sold 48,493 shares (Common Stock) at a price of $60.11 per share, resulting in proceeds of $2,914,914. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.5K
0% 3M change
0% 12M change
Total Value Held $890,657

Christopher Bowden Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jun 18 2021
SELL
Open market or private sale
$2,914,914 $60.11 p/Share
48,493 Reduced 75.79%
15,487 Common Stock
Jun 18 2021
BUY
Exercise of conversion of derivative security
$2,186,065 $45.08 p/Share
48,493 Added 43.12%
63,980 Common Stock
Jun 17 2021
SELL
Open market or private sale
$150,170 $60.02 p/Share
2,502 Reduced 13.91%
15,487 Common Stock
Jun 17 2021
BUY
Exercise of conversion of derivative security
$99,480 $39.76 p/Share
2,502 Added 12.21%
17,989 Common Stock
Jun 10 2021
SELL
Open market or private sale
$1,252,431 $60.06 p/Share
20,853 Reduced 57.38%
15,487 Common Stock
Jun 10 2021
BUY
Exercise of conversion of derivative security
$829,115 $39.76 p/Share
20,853 Added 36.46%
36,340 Common Stock
Jun 09 2021
SELL
Open market or private sale
$430,084 $60.16 p/Share
7,149 Reduced 31.58%
15,487 Common Stock
Jun 09 2021
BUY
Exercise of conversion of derivative security
$284,244 $39.76 p/Share
7,149 Added 24.0%
22,636 Common Stock
Jun 08 2021
SELL
Open market or private sale
$400,967 $60.07 p/Share
6,675 Reduced 30.12%
15,487 Common Stock
Jun 08 2021
BUY
Exercise of conversion of derivative security
$265,398 $39.76 p/Share
6,675 Added 23.15%
22,162 Common Stock
Jun 07 2021
SELL
Open market or private sale
$256,251 $60.04 p/Share
4,268 Reduced 21.6%
15,487 Common Stock
Jun 07 2021
BUY
Exercise of conversion of derivative security
$169,696 $39.76 p/Share
4,268 Added 17.77%
19,755 Common Stock
Apr 20 2021
SELL
Open market or private sale
$793,639 $55.11 p/Share
14,401 Reduced 48.18%
15,487 Common Stock
Apr 20 2021
BUY
Exercise of conversion of derivative security
$539,461 $37.46 p/Share
14,401 Added 32.52%
29,888 Common Stock
Apr 19 2021
SELL
Open market or private sale
$177,064 $55.16 p/Share
3,210 Reduced 17.17%
15,487 Common Stock
Apr 19 2021
BUY
Exercise of conversion of derivative security
$112,864 $35.16 p/Share
3,210 Added 14.65%
18,697 Common Stock
Feb 24 2021
SELL
Payment of exercise price or tax liability
-
986 Reduced 6.01%
15,410 Common Stock
Feb 22 2021
BUY
Exercise of conversion of derivative security
-
3,334 Added 16.9%
16,396 Common Stock
Feb 16 2021
SELL
Payment of exercise price or tax liability
-
2,069 Reduced 13.67%
13,062 Common Stock
Feb 16 2021
BUY
Exercise of conversion of derivative security
-
2,750 Added 15.38%
15,131 Common Stock
Feb 14 2021
BUY
Exercise of conversion of derivative security
-
4,000 Added 24.42%
12,381 Common Stock

Also insider at

TCRT
Alaunos Therapeutics, Inc. Healthcare
CB

Christopher Bowden

Chief Medical Officer
Cambridge, MA

Track Institutional and Insider Activities on AGIO

Follow AGIOS PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells AGIO shares.

Notify only if

Insider Trading

Get notified when an Agios Pharmaceuticals, Inc. insider buys or sells AGIO shares.

Notify only if

News

Receive news related to AGIOS PHARMACEUTICALS, INC.

Track Activities on AGIO